SWTX Stock - SpringWorks Therapeutics, Inc.
Unlock GoAI Insights for SWTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $191.59M | $5.45M | $6.15M | N/A | $35.00M |
| Gross Profit | $179.04M | $5.03M | $4.25M | $-490,000 | $34.65M |
| Gross Margin | 93.4% | 92.3% | 69.2% | N/A | 99.0% |
| Operating Income | $-278,131,000 | $-343,013,000 | $-280,674,000 | $-173,468,000 | $-46,324,000 |
| Net Income | $-258,131,000 | $-325,104,000 | $-277,417,000 | $-173,212,000 | $-45,574,000 |
| Net Margin | -134.7% | -5968.5% | -4513.0% | N/A | -130.2% |
| EPS | $-3.48 | $-5.15 | $-5.21 | $-3.59 | $-1.05 |
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 20th 2024 | Evercore ISI | Initiation | Outperform | $60 |
| February 5th 2024 | Guggenheim | Initiation | Buy | $75 |
| December 1st 2022 | BofA Securities | Initiation | Buy | $45 |
Earnings History & Surprises
SWTXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 6, 2025 | $-0.81 | $-0.54 | +33.3% | ✓ BEAT |
Q2 2025 | May 9, 2025 | $-0.81 | $-1.11 | -37.0% | ✗ MISS |
Q1 2025 | Feb 20, 2025 | $-0.72 | $-1.04 | -44.4% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.76 | $-0.72 | +5.3% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-1.12 | $-0.54 | +51.8% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-1.17 | $-1.18 | -0.9% | ✗ MISS |
Q1 2024 | Feb 27, 2024 | $-1.25 | $-1.44 | -15.2% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-1.31 | $-1.27 | +3.1% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $-1.25 | $-1.25 | 0.0% | = MET |
Q2 2023 | May 3, 2023 | $-1.25 | $-1.18 | +5.6% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-1.21 | $-1.19 | +1.7% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-1.31 | $-1.37 | -4.6% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-1.26 | $-1.41 | -11.9% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-1.07 | $-1.26 | -17.8% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-0.87 | $-1.15 | -32.2% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.77 | $-0.84 | -9.1% | ✗ MISS |
Q3 2021 | Aug 4, 2021 | $-0.70 | $-0.97 | -38.6% | ✗ MISS |
Q2 2021 | May 6, 2021 | $-0.51 | $-0.62 | -21.6% | ✗ MISS |
Q1 2021 | Feb 25, 2021 | $-0.10 | $0.30 | +400.0% | ✓ BEAT |
Q4 2020 | Nov 12, 2020 | $-0.49 | $-0.51 | -4.1% | ✗ MISS |
Frequently Asked Questions about SWTX
What is SWTX's current stock price?
What is the analyst price target for SWTX?
What sector is SpringWorks Therapeutics, Inc. in?
What is SWTX's market cap?
Does SWTX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SWTX for comparison